vTv Therapeutics (NASDAQ:VTVT) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a note issued to investors on Saturday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners initiated coverage on shares of vTv Therapeutics in a research note on Monday, December 9th. They issued a “buy” rating and a $35.00 price objective for the company.

vTv Therapeutics Price Performance

Shares of NASDAQ VTVT opened at $21.70 on Friday. The company has a market capitalization of $69.22 million, a P/E ratio of -4.79 and a beta of 0.73. The business’s 50-day moving average price is $15.23 and its two-hundred day moving average price is $14.89. vTv Therapeutics has a one year low of $8.10 and a one year high of $30.99.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.88) earnings per share for the quarter.

Institutional Investors Weigh In On vTv Therapeutics

Large investors have recently added to or reduced their stakes in the stock. FMR LLC acquired a new position in shares of vTv Therapeutics during the third quarter worth approximately $2,402,000. Geode Capital Management LLC raised its position in shares of vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 1,327 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new stake in shares of vTv Therapeutics in the fourth quarter valued at about $25,000. Institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.